

Gene Section

Review

ASH2L (ash2 (absent, small, or homeotic)-like (Drosophila))

Paul F South, Scott D Briggs

Department of Biochemistry and Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, USA (PFS, SDB)

Published in Atlas Database: August 2011

Online updated version : <http://AtlasGeneticsOncology.org/Genes/ASH2LID44404ch8p11.html>
DOI: 10.4267/2042/47265

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: ASH2, ASH2L1, ASH2L2, Bre2

HGNC (Hugo): ASH2L

Location: 8p11.23

DNA/RNA

Description

16 exons spanning over 34218 base pairs.

Transcription

mRNA is 2368 base pairs long.

Protein

Description

There are three known isoforms of ASH2L (Wang et al., 2001). Isoform 1 is considered the canonical sequence and consists of 628 amino acids (Wang et al., 2001). Isoform 2 is missing amino acids 1-94 and 541-

573 from isoform 1 (Wang et al., 2001). Isoform 3 is missing the amino acids 1-94 from isoform 1 (figure 2) (Wang et al., 2001). There are four identified domains within ASH2L which include a N-terminus containing a PHD finger and a winged helix motif (WH) and the C-terminus containing a SPRY domain and the Sdc1 DPY-30 Interacting domain (SDI) (figure 2) (Chen et al., 2011; Roguev et al., 2001; Sarvan et al., 2011; South et al., 2010; Wang et al., 2001). The largest of the three identified domains within ASH2L is the SPRY domain, which is also conserved from yeast to humans. SPRY domains were originally named after the **SP**Ia kinase and the **RY**anodine receptor proteins in which it was first identified (Rhodes et al., 2005). Crystal structures of SPRY domain containing proteins show primarily a beta-sandwich structure with extending loops (Filippakopoulos et al., 2010; Kuang et al., 2009; Simonet et al., 2007; Woo et al., 2006b). The SPRY domain is thought to be a specific protein-protein interaction domain




Figure 1. Map of chromosome 8 with region 8p11.2 highlighted as the location of the gene ASH2L.




Figure 2. Schematic model of the three known isoforms of ASH2L and the amino acid sequence changes compared to the canonical isoform 1 (aa 1-628). The positions of known domains within ASH2L are displayed. PHD finger (aa 95-161), WH motif (aa 162-273), SPRY domain (aa 360-583), and SDI domain (aa 602-628). Isoform 2 and 3 are numbered according to isoform 1.

with specific partners, but instead of recognizing a particular motif or interaction domain the SPRY domain binds to interaction partners using non-conserved binding loops (Filippakopoulos et al., 2010; Woo et al., 2006a; Woo et al., 2006b). Recent work has shown that the C-terminus of ASH2L that contains the SPRY domain and the SDI domain are able to interact with the other MLL complex member RBBP5 in vitro (Avdic et al., 2011).

ASH2L also contains a putative Plant Homeo Domain (PHD) finger in its N-terminus (Wang et al., 2001). The structure of PHD fingers shows that conserved cysteine and histidine residues bind to Zn^{2+} ions (Champagne et al., 2008; Champagne and Kutateladze, 2009; van Ingen et al., 2008). There is no known function attributed to the PHD finger in ASH2L, though in conjunction with the winged helix motif it may be necessary for DNA binding.

The N-terminal winged helix (WH) motif was recently discovered when the crystal structure of the N-terminus of ASH2L was solved (Chen et al., 2011; Sarvan et al., 2011). Using in vitro DNA binding analyses as well as chromatin immunoprecipitation, it was determined that ASH2L can bind DNA at the HS2 promoter region and the beta-globin locus as well as non-specific DNA sequence (Chen et al., 2011; Sarvan et al., 2011).

The last identifiable domain within ASH2L is the SDI domain. There is no structural information on the SDI domain but the functional importance was determined biochemically. The function of the SDI domain was determined using in vitro binding experiments. ASH2L was shown to directly interact with DPY-30 without any additional MLL or Set1 complex components (South et al., 2010). The function of the SDI domain is conserved from yeast to humans because the yeast ASH2L homolog Bre2 was also shown to interact with the DPY-30 homolog Sdc1 (South et al., 2010). There are conserved hydrophobic residues in both the SDI domain of ASH2L and the Dpy-30 domain of DPY-30 that are important for binding, which suggests that the

interaction between the SDI domain of ASH2L and the DPY-30 domain of DPY-30 is through hydrophobic interactions (South et al., 2010).

Expression

Northern blot analysis from multiple tissues revealed that ASH2L expression is expressed in 14 different tissue types with the highest expression in fetal liver and testes (Lüscher-Firzloff et al., 2008). ASH2L transcripts were also found to be expressed higher in various Leukemia cell lines, such as K562, Hel, and Dami cells (Lüscher-Firzloff et al., 2008).

Localisation

Nucleus.

Function

Biochemical data has shown that ASH2L is found in a methyltransferase core complex composed of ASH2L, RBBP5, DPY30, WDR5, and the catalytic SET domain containing protein. This core complex is highly conserved and similar to the budding yeast Set1 complex that consists of Set1 (MLL/SET1), Bre2 (ASH2L), Swd1 (RBBP5), Swd3 (WDR5), Swd2 (WDR82), Sdc1 (DPY-30), Spp1 (CFP1/CGBP). ASH2L is also known to associate with numerous additional factors. Many of these additional factors are thought to associate with ASH2L and the H3K4 methyltransferase complexes to target the complex to specific sites within the genome (Cho et al., 2007; Dou et al., 2006; Hughes et al., 2004; Steward et al., 2006; Stoller et al., 2010). Knock-down of ASH2L using siRNA globally decreases H3K4 trimethylation (Dou et al., 2006; Steward et al., 2006). ASH2L and H3K4 methylation both appear to play a key role in oncogenesis (Hess, 2006). ASH2L is found to be over abundant in many cancer cell lines and knock-down of ASH2L by siRNA can prevent tumorigenesis (Lüscher-Firzloff et al., 2008). Recent work has suggested that ASH2L in combination with WDR5 and RBBP5 exhibits H3K4 methyltransferase activity (Cao et al.,

2010; Patel et al., 2009; Patel et al., 2011). In addition, this catalytic activity is not dependent on the SET domain containing proteins such as MLL1 (Cao et al., 2010; Patel et al., 2009; Patel et al., 2011).

Alternative to ASH2L's function in H3K4 methylation ASH2L may also be playing a role in endosomal trafficking (Xu et al., 2009). ASH2L, DPY-30 and WDR5 were originally implicated in endosomal trafficking when siRNA knock-down of these genes increased the amount of internalized CD8-CIMPR and overexpression increased the amount of cells displaying a altered CIMPR distribution (Xu et al., 2009).

Homology

ASH2L has homologs in eukaryotes from yeast to humans.

Implicated in

Various cancers

Note

ASH2L mRNA expression does not appear to be misregulated in human cancer cell or primary cell lines. However, expression of ASH2L protein is increased in many cancer cell lines as well as tumor samples (Lüscher-Firzlaff et al., 2008). There was detectable increased staining in the nucleus of ASH2L protein in a wide array of tumors including squamous cell carcinoma of the larynx and the cervix, melanomas, adenocarcinoma of the pancreas, and acinar and ductal breast cancers (Lüscher-Firzlaff et al., 2008). ASH2L protein appears to be more stable in cancer cell lines compared to the normal cell line counterparts and knockdown of ASH2L can prevent tumorigenesis suggesting a role in tumor cell proliferation (Lüscher-Firzlaff et al., 2008).

References

Roguev A, Schaft D, Shevchenko A, Pijnappel WW, Wilm M, Aasland R, Stewart AF. The *Saccharomyces cerevisiae* Set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4. *EMBO J*. 2001 Dec 17;20(24):7137-48

Wang J, Zhou Y, Yin B, Du G, Huang X, Li G, Shen Y, Yuan J, Qiang B. ASH2L: alternative splicing and downregulation during induced megakaryocytic differentiation of multipotential leukemia cell lines. *J Mol Med (Berl)*. 2001 Jul;79(7):399-405

Hess JL.. MLL: Deep Insight. *Atlas Genet Cytogenet Oncol Haematol*. August 2003 .

Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M.. Menin associates with a trithorax family histone methyltransferase complex and with the *hoxc8* locus. *Mol Cell*. 2004 Feb 27;13(4):587-97.

Rhodes DA, de Bono B, Trowsdale J.. Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence? *Immunology*. 2005 Dec;116(4):411-7. (REVIEW)

Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD, Roeder RG.. Regulation of MLL1 H3K4

methyltransferase activity by its core components. *Nat Struct Mol Biol*. 2006 Aug;13(8):713-9. Epub 2006 Jul 30.

Steward MM, Lee JS, O'Donovan A, Wyatt M, Bernstein BE, Shilatifard A.. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. *Nat Struct Mol Biol*. 2006 Sep;13(9):852-4. Epub 2006 Aug 6.

Woo JS, Imm JH, Min CK, Kim KJ, Cha SS, Oh BH.. Structural and functional insights into the B30.2/SPRY domain. *EMBO J*. 2006a Mar 22;25(6):1353-63. Epub 2006 Feb 23.

Woo JS, Suh HY, Park SY, Oh BH.. Structural basis for protein recognition by B30.2/SPRY domains. *Mol Cell*. 2006b Dec 28;24(6):967-76.

Cho YW, Hong T, Hong S, Guo H, Yu H, Kim D, Guszczynski T, Dressler GR, Copeland TD, Kalkum M, Ge K.. PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. *J Biol Chem*. 2007 Jul 13;282(28):20395-406. Epub 2007 May 11.

Simonet T, Dulermo R, Schott S, Palladino F.. Antagonistic functions of SET-2/SET1 and HPL/HP1 proteins in *C. elegans* development. *Dev Biol*. 2007 Dec 1;312(1):367-83. Epub 2007 Oct 29.

Champagne KS, Saksouk N, Pena PV, Johnson K, Ullah M, Yang XJ, Cote J, Kutateladze TG.. The crystal structure of the ING5 PHD finger in complex with an H3K4me3 histone peptide. *Proteins*. 2008 Sep;72(4):1371-6.

Lüscher-Firzlaff J, Gawlista I, Vervoorts J, Kapelle K, Braunschweig T, Walsemann G, Rodgarkia-Schamberger C, Schuchlauth H, Dreschers S, Kremmer E, Lilischkis R, Cerni C, Wellmann A, Lüscher B.. The human trithorax protein hASH2 functions as an oncoprotein. *Cancer Res*. 2008 Feb 1;68(3):749-58.

van Ingen H, van Schaik FM, Wienk H, Ballering J, Rehmann H, Dechesne AC, Kruijzer JA, Liskamp RM, Timmers HT, Boelens R.. Structural insight into the recognition of the H3K4me3 mark by the TFIID subunit TAF3. *Structure*. 2008 Aug 6;16(8):1245-56.

Champagne KS, Kutateladze TG.. Structural insight into histone recognition by the ING PHD fingers. *Curr Drug Targets*. 2009 May;10(5):432-41. (REVIEW)

Kuang Z, Yao S, Xu Y, Lewis RS, Low A, Masters SL, Willson TA, Kolesnik TB, Nicholson SE, Garrett TJ, Norton RS.. SPRY domain-containing SOCS box protein 2: crystal structure and residues critical for protein binding. *J Mol Biol*. 2009 Feb 27;386(3):662-74. Epub 2009 Jan 6.

Patel A, Dharmarajan V, Vought VE, Cosgrove MS.. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. *J Biol Chem*. 2009 Sep 4;284(36):24242-56. Epub 2009 Jun 25.

Xu Z, Gong Q, Xia B, Groves B, Zimmermann M, Mugler C, Mu D, Matsumoto B, Seaman M, Ma D.. A role of histone H3 lysine 4 methyltransferase components in endosomal trafficking. *J Cell Biol*. 2009 Aug 10;186(3):343-53. Epub 2009 Aug 3.

Cao F, Chen Y, Cierpicki T, Liu Y, Basrur V, Lei M, Dou Y.. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. *PLoS One*. 2010 Nov 23;5(11):e14102.

Filippakopoulos P, Low A, Sharpe TD, Uppenberg J, Yao S, Kuang Z, Savitsky P, Lewis RS, Nicholson SE, Norton RS, Bullock AN.. Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4. *J Mol Biol*. 2010 Aug 20;401(3):389-402. Epub 2010 Jun 16.

South PF, Fingerman IM, Mersman DP, Du HN, Briggs SD.. A conserved interaction between the SDI domain of Bre2 and the Dpy-30 domain of Sdc1 is required for histone methylation and gene expression. *J Biol Chem*. 2010 Jan 1;285(1):595-607. Epub 2009 Nov 6.

Stoller JZ, Huang L, Tan CC, Huang F, Zhou DD, Yang J, Gelb BD, Epstein JA.. Ash2l interacts with Tbx1 and is required during early embryogenesis. *Exp Biol Med (Maywood)*. 2010 May;235(5):569-76.

Avdic V, Zhang P, Lanouette S, Groulx A, Tremblay V, Brunzelle J, Couture JF.. Structural and biochemical insights into MLL1 core complex assembly. *Structure*. 2011 Jan 12;19(1):101-8.

Chen Y, Wan B, Wang KC, Cao F, Yang Y, Protacio A, Dou Y, Chang HY, Lei M.. Crystal structure of the N-terminal region of human Ash2L shows a winged-helix motif involved in DNA binding. *EMBO Rep*. 2011 Jun 10;12(8):797-803. doi: 10.1038/embor.2011.101.

Patel A, Vought VE, Dharmarajan V, Cosgrove MS.. A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex. *J Biol Chem*. 2011 Feb 4;286(5):3359-69. Epub 2010 Nov 24.

Sarvan S, Avdic V, Tremblay V, Chaturvedi CP, Zhang P, Lanouette S, Blais A, Brunzelle JS, Brand M, Couture JF.. Crystal structure of the trithorax group protein ASH2L reveals a forkhead-like DNA binding domain. *Nat Struct Mol Biol*. 2011 Jun 5;18(7):857-9. doi: 10.1038/nsmb.2093.

This article should be referenced as such:

South PF, Briggs SD. ASH2L (*ash2* (absent, small, or homeotic)-like (*Drosophila*)). *Atlas Genet Cytogenet Oncol Haematol*. 2012; 16(1):30-33.
